Prudential Financial
ALXN

Prudential Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

Prudential Financial’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-189,305
Closed -$34.8M – 2665
2021
Q2 		$34.8M Sell
189,305
-9,459
-5% -$1.62M 0.05% 356
2021
Q1 		$30.4M Sell
198,764
-174,656
-47% -$27M 0.05% 346
2020
Q4 		$58.3M Buy
373,420
+29,204
+8% +$3.75M 0.1% 191
2020
Q3 		$39.4M Buy
344,216
+50,867
+17% +$5.49M 0.07% 242
2020
Q2 		$32.9M Sell
293,349
-96,395
-25% -$10.2M 0.06% 276
2020
Q1 		$35M Sell
389,744
-279,004
-42% -$27.4M 0.08% 254
2019
Q4 		$72.3M Sell
668,748
-5,371
-0.8% -$574K 0.11% 187
2019
Q3 		$66M Sell
674,119
-508,406
-43% -$57.3M 0.1% 196
2019
Q2 		$155M Buy
1,182,525
+549,403
+87% +$70.8M 0.24% 85
2019
Q1 		$85.6M Buy
633,122
+200,907
+46% +$25M 0.14% 146
2018
Q4 		$42.1M Buy
432,215
+118,103
+38% +$14M 0.07% 275
2018
Q3 		$43.7M Sell
314,112
-41,209
-12% -$5.17M 0.06% 321
2018
Q2 		$44.1M Buy
355,321
+85,763
+32% +$10M 0.07% 325
2018
Q1 		$30M Sell
269,558
-163,390
-38% -$19.5M 0.05% 463
2017
Q4 		$51.8M Buy
432,948
+44,780
+12% +$5.45M 0.07% 314
2017
Q3 		$54.5M Buy
388,168
+680
+0.2% +$92.4K 0.08% 280
2017
Q2 		$47.1M Buy
387,488
+77,360
+25% +$9M 0.07% 316
2017
Q1 		$37.6M Buy
310,128
+3,144
+1% +$405K 0.06% 362
2016
Q4 		$37.6M Sell
306,984
-3,820
-1% -$467K 0.06% 348
2016
Q3 		$38.1M Sell
310,804
-66,224
-18% -$8.52M 0.06% 338
2016
Q2 		$44M Buy
377,028
+31,310
+9% +$4.44M 0.07% 276
2016
Q1 		$48.1M Buy
345,718
+9,460
+3% +$1.39M 0.09% 245
2015
Q4 		$64.1M Buy
336,258
+450
+0.1% +$78.6K 0.12% 181
2015
Q3 		$52.5M Buy
335,808
+33,970
+11% +$6.2M 0.1% 207
2015
Q2 		$54.6M Sell
301,838
-408,368
-57% -$70.5M 0.1% 207
2015
Q1 		$123M Sell
710,206
-140,870
-17% -$25.5M 0.21% 100
2014
Q4 		$157M Sell
851,076
-4,710
-0.6% -$873K 0.29% 70
2014
Q3 		$142M Buy
855,786
+59,707
+8% +$9.81M 0.27% 76
2014
Q2 		$124M Buy
796,079
+35,303
+5% +$5.57M 0.22% 102
2014
Q1 		$116M Buy
760,776
+107,510
+16% +$17.1M 0.22% 106
2013
Q4 		$86.9M Sell
653,266
-47,910
-7% -$5.75M 0.17% 131
2013
Q3 		$81.4M Buy
701,176
+51,250
+8% +$5.62M 0.17% 132
2013
Q2 		$60M Buy
+649,926
New +$62.6M 0.13% 171

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Prudential Financial's ALXN Position: Q3 2021 in Review

Prudential Financial sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 189,305 shares — an estimated $34.8M sold.

Prudential Financial first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $157M in Q4 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Prudential Financial reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Prudential Financial sold 189,305 Alexion Pharmaceuticals shares in Q3 2021, an estimated $34.8M.
  • Prudential Financial first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Prudential Financial's Alexion Pharmaceuticals position peaked at $157M in Q4 2014.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Prudential Financial's 13F filing for Q3 2021, filed 15 Nov 2021.